Quick-relief beta-agonists help you breathe better by relaxing the muscles of your airways. They are short-acting, which means they stay in your system only for a short time.

Some people take them just before exercising. Ask your provider if you should do this.

If you need to use these medicines more than 3 times a week, or if you use more than one canister a month, your COPD probably is not under control. You should contact your provider to see if any changes should be made.

Quick-relief beta-agonists inhalers include:

• Albuterol (ProAir HFA; Proventil HFA; Ventolin HFA)
• Levalbuterol (Xopenex HFA)
• Albuterol and ipratropium (Combivent Respimat)

Most of the time, these medicines are used as metered dose inhalers (MDI) with a spacer. Sometimes, especially if you have a flare-up, they are used with a nebulizer.

Side effects might include:

• Anxiety.
• Tremor.
• Restlessness.
• Headache.
• Fast or irregular heartbeats. Call your provider right away if you have this side effect.

Some of these medicines also exist in pills, but the side effects are a lot more significant, so they are very rarely used that way.

There is one medicine, ipratropium (Atrovent HFA), which works slower than beta-agonists, but faster than other long-acting medicines.

Oral steroids (also called corticosteroids) are medicines you take by mouth, as pills, capsules, or liquids. They are not quick-relief medicines, but are often given for 7 to 14 days when your symptoms flare-up. Sometimes you might have to take them for longer.

Oral steroids include:

• Methylprednisolone
• Prednisone
• Prednisolone

COPD - quick-relief drugs; Chronic obstructive pulmonary disease - control drugs; Chronic obstructive airways disease - quick-relief drugs; Chronic obstructive lung disease - quick-relief drugs; Chronic bronchitis - quick-relief drugs; Emphysema - quick-relief drugs; Bronchitis - chronic - quick-relief drugs; Chronic respiratory failure - quick-relief drugs; Bronchodilators - COPD - quick-relief drugs; COPD - short-acting beta agonist inhaler

Anderson B, Brown H, Bruhl E, et al. Institute for Clinical Systems Improvement website. Health Care Guideline: Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report. goldcopd.org/2024-gold-report/. Accessed May 16, 2024.

Han MK, Lazarus SC. COPD: clinical diagnosis and management. In: Broaddus VC, Ernst JD, King TE, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, PA: Elsevier; 2022:chap 64.

Reilly J. Chronic obstructive pulmonary disease. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 76.

US Department of Veterans Affairs website. VA/DoD Clinical Practice Guideline for The Management Of Chronic Obstructive Pulmonary Disease, Version 3.0, April 2021. www.healthquality.va.gov/guidelines/CD/copd/VADoDCOPDCPGFinal508.pdf. Accessed May 16, 2024.

Waller DG. Asthma and chronic obstructive pulmonary disease. In: Waller DG, ed. Medical Pharmacology and Therapeutics. 6th ed. Philadelphia, PA: Elsevier; 2022:chap 12.

Updated by: Allen J. Blaivas, DO, Division of Pulmonary, Critical Care, and Sleep Medicine, VA New Jersey Health Care System, Clinical Assistant Professor, Rutgers New Jersey Medical School, East Orange, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.